Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBIT (2020 - 2025)

RxSight's EBIT history spans 6 years, with the latest figure at $28.7 million for Q4 2025.

  • For Q4 2025, EBIT rose 27.65% year-over-year to $28.7 million; the TTM value through Dec 2025 reached -$8.2 million, down 41.9%, while the annual FY2025 figure was -$8.2 million, 41.86% down from the prior year.
  • EBIT reached $28.7 million in Q4 2025 per RXST's latest filing, up from -$12.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $29.0 million in Q4 2023 to a low of -$16.6 million in Q1 2022.
  • Average EBIT over 5 years is -$7.0 million, with a median of -$12.8 million recorded in 2023.
  • Peak YoY movement for EBIT: tumbled 76.62% in 2021, then surged 293.66% in 2023.
  • A 5-year view of EBIT shows it stood at -$14.7 million in 2021, then decreased by 2.23% to -$15.0 million in 2022, then soared by 293.66% to $29.0 million in 2023, then fell by 22.58% to $22.5 million in 2024, then increased by 27.65% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's EBIT are $28.7 million (Q4 2025), -$12.2 million (Q3 2025), and -$14.0 million (Q2 2025).